Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Why Mind Medicine Stock Is Skyrocketing Today

Source The Motley Fool

Mind Medicine (NASDAQ: MNMD) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m. ET and had been up as much as 20.7% on the day earlier in the session.

Mind Medicine's valuation is surging following Robert F. Kennedy Jr.'s approval as health and human services (HHS) secretary in yesterday's Senate vote. Kennedy has previously voiced support for psychedelics as therapeutic treatments.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Mind Medicine stock soars on RFK Jr.'s HHS confirmation

In a 52-to-48 vote yesterday, RJK Jr. was approved as the U.S.'s new HHS secretary. Among President Donald Trump's cabinet nominations, Kennedy's confirmation vote was viewed as one of the more likely to fall through. But he was confirmed for the cabinet role with nearly unanimous Republican support. Sen. Mitch McConnell from Kentucky was the only Republican to vote against Kennedy.

RFK Jr. has previously said that he supports the use of psychedelic drugs as therapeutic treatments in some instances. With the new HHS secretary being a supporter of Mind Medicine's core competency, it's possible that the biotech company will have an easier time bringing its products to the market.

What's next for Mind Medicine?

Political dynamics appear to be shifting in Mind Medicine's favor. The clinical-stage biopharmaceutical company has yet to record any revenue, but it's making progress with testing phases for its core treatments.

On Dec. 16, the company published a press release announcing that its phase 3 study for lysergide D-tartrate (LSD) as a treatment for generalized anxiety disorder was scheduled to kick off in the first half of 2025. Then on Jan. 16, the company announced that the first patient in the clinical test had been dosed. Roughly 250 patients are expected to be tested in the trial, and the results are likely to have a big impact on Mind Medicine's share price.

Should you invest $1,000 in Mind Medicine (MindMed) right now?

Before you buy stock in Mind Medicine (MindMed), consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mind Medicine (MindMed) wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $829,128!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 7, 2025

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Gold prices rise to over one-month high on softer dollar, bond yields Gold prices climbed on Tuesday to their highest point in more than a month, supported by a weaker U.S. dollar and lower Treasury yields.

Author Reuters

Jul 22, 2025

Gold prices climbed on Tuesday to their highest point in more than a month, supported by a weaker U.S. dollar and lower Treasury yields.

Gold holds steady below $4,150 amid elevated US yields Gold price (XAU/USD) trades on a flat note near $4,140 during the early Asian session on Tuesday. Pressure from a stronger US Dollar (USD) and elevated US Treasury yields was offset by reduced expectations of a Federal Reserve (Fed) rate hike this month.

Author FXStreet

Oct 06, Tue

Gold price (XAU/USD) trades on a flat note near $4,140 during the early Asian session on Tuesday. Pressure from a stronger US Dollar (USD) and elevated US Treasury yields was offset by reduced expectations of a Federal Reserve (Fed) rate hike this month.

WTI rises to near $89.50 as Middle East supply threats offset Persian Gulf recovery West Texas Intermediate (WTI) oil price extends its gains for the second successive day, trading around $89.50 per barrel during the Asian hours on Wednesday. Crude oil climbed as persistent risks to Middle East energy flows overshadowed signs of rising supply from the region.

Author FXStreet

Oct 07, Wed

West Texas Intermediate (WTI) oil price extends its gains for the second successive day, trading around $89.50 per barrel during the Asian hours on Wednesday. Crude oil climbed as persistent risks to Middle East energy flows overshadowed signs of rising supply from the region.

Gold falls to a two-month low as real yields bite — can $4,000 hold?Gold hit a two-month low on 7 October, with spot touching roughly $4,090 and COMEX December futures closing at $4,140.70, even as the New York Fed's one-year inflation expectation rose to 3.9% — its highest since May 2023. The paradox resolves through real yields: the 30-year Treasury yield reached 5.732% intraday, its highest since 2002. Here are the levels, the institutional split, and the scenarios into tonight's jobless claims and 30-year auction.

Author Irene Q.

Yesterday 07: 32

Gold hit a two-month low on 7 October, with spot touching roughly $4,090 and COMEX December futures closing at $4,140.70, even as the New York Fed's one-year inflation expectation rose to 3.9% — its highest since May 2023. The paradox resolves through real yields: the 30-year Treasury yield reached 5.732% intraday, its highest since 2002. Here are the levels, the institutional split, and the scenarios into tonight's jobless claims and 30-year auction.

【Daily Brief】Gold rebounds 1% off a two-month low, Nasdaq drops 1.25% and yields ease — the storm premium keeps WTI near $91 Gold trades at $4,174 after rebounding from Wednesday's $4,090 two-month low, the Nasdaq fell 1.25% while the Dow edged higher, and the 10-year Treasury eased to 5.23% from the week's highs. Hurricane Isaias keeps about 25% of Gulf output shut in with WTI near $91, and bitcoin holds below $82,000. The next scheduled tests are the EIA report on 15 October and the FOMC on 27-28 October.

Author Irene Q.

6 hours ago

Gold trades at $4,174 after rebounding from Wednesday's $4,090 two-month low, the Nasdaq fell 1.25% while the Dow edged higher, and the 10-year Treasury eased to 5.23% from the week's highs. Hurricane Isaias keeps about 25% of Gulf output shut in with WTI near $91, and bitcoin holds below $82,000. The next scheduled tests are the EIA report on 15 October and the FOMC on 27-28 October.

Popular Symbols